Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: A retrospective, international study

Haematologica

Volumn 99, Issue 2, 2014, Pages 299-307

  Blink, Marjolein ^a   Zimmermann, Martin ^b   von Neuhoff, Christine ^b   Reinhardt, Dirk ^b   de Haas, Valerie ^c   Hasle, Henrik ^d   O'Brien, Maureen M ^e   Stark, Batia ^f   Tandonnet, Julie ^g   Pession, Andrea ^h   Tousovska, Katerina ⁱ   Cheuk, Daniel K L ^j   Kudo, Kazuko ^k   Taga, Takashi ^l   Rubnitz, Jeffrey E ^m   Haltrich, Iren ⁿ   Balwierz, Walentyna ^o   Pieters, Rob ^a,c   Forestier, Erik ^p   Johansson, Bertil ^q   van den Heuvel Eibrink, Marry M ^a,c   Michel Zwaan, C ^a,c   more..

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^g Children's Hospital   (France)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^j UNIVERSITY OF HONG KONG   (Hong Kong)

^k SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^l SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^m Jude Children's Research Hospital   (United States)

ⁿ SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^o JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^p UMEÅ UNIVERSITY   (Sweden)

^q LUND UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE;

ARTICLE; CANCER PROGNOSIS; CHILD; CHROMOSOME ABERRATION; DOWN SYNDROME; EVENT FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; INCIDENCE; INFANT; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOID LEUKEMIA; OVERALL SURVIVAL; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ABNORMAL KARYOTYPE; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 21; DISEASE-FREE SURVIVAL; DOWN SYNDROME; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, MYELOID; MALE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84896716441     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.089425     Document Type: Article

References (35)

1. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355(9199):165-9.
2. Zwaan MC, Reinhardt D, Hitzler J, Vyas P. Acute leukemias in children with Down syndrome. Pediatr Clin North Am. 2008;55 (1):53-70.
3. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17(2):277-82.
4. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia. 2005;19(8):1355-60.
5. Creutzig U, Ritter J, Vormoor J, Ludwig WD, Niemeyer C, Reinisch I, et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia. 1996;10(11):1677-86.
6. Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol. 2003;21(18):3415-22.
7. Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley JD, Howells WB, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood. 1998;91(2): 608-15.
8. Rao A, Hills RK, Stiller C, Gibson BE, de Graaf SS, Hann IM, et al. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol. 2006;132(5):576-83.
9. Zeller B, Gustafsson G, Forestier E, Abrahamsson J, Clausen N, Heldrup J, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol. 2005;128(6):797-804.
10. Zipursky A, Thorner P, De Harven E, Christensen H, Doyle J. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res. 1994;18(3): 163-71.
11. Taub JW, Huang X, Matherly LH, Stout ML, Buck SA, Massey GV, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood. 1999;94(4):1393-400.
12. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Janka-Schaub GE, van Zantwijk CH, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood. 2002;99(1):245-51.
13. Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101(11):4298-300.
14. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32(1):148-52.
15. Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. 2005;5(1):11-20.
16. Kanezaki R, Toki T, Terui K, Xu G, Wang R, Shimada A, et al. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood. 2010;116(22): 4631-8.
17. Sorrell AD, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Hathaway L, et al. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Cancer. 2012;118(19): 4806-14.
18. Hasle H, Abrahamsson J, Arola M, Karow A, O'Marcaigh A, Reinhardt D, et al. Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia. 2008;22(7):1428-30.
19. Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008;111(6):2991-8.
20. Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalova K, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008;111(3):1575-83.
21. Litz CE, Davies S, Brunning RD, Kueck B, Parkin JL, Gajl Peczalska K, et al. Acute leukemia and the transient myeloproliferative disorder associated with Down syndrome: morphologic, immunophenotypic and cytogenetic manifestations. Leukemia. 1995;9(9):1432-9.
22. Kaneko Y, Rowley JD, Variakojis D, Chilcote RR, Moohr JW, Patel D. Chromosome abnormalities in Down's syndrome patients with acute leukemia. Blood. 1981;58(3):459-66.
23. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica. 2007;92(11):1519-32.
24. Hasle H, Alonzo TA, Auvrignon A, Behar C, Chang M, Creutzig U, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood. 2007;109(11):4641-7.
25. Ravindranath Y. Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy. J Clin Oncol. 2003;21(18):3385-7.
26. Pine SR, Guo Q, Yin C, Jayabose S, Levendoglu-Tugal O, Ozkaynak MF, et al. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome. Leuk Res. 2005;29(11):1353-6.
27. Hasle H, Lund B, Nyvold CG, Hokland P, Ostergaard M. WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder. Leuk Res. 2006;30(5):543-6.
28. Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, et al. Outcome of Transplantation for acute myelogenous leukemia in children with down syndrome. Biol Blood Marrow Transplant. 2013;19(6): 893-7.
29. Metzeler KH, Dufour A, Benthaus T, Hummel M, Sauerland MC, Heinecke A, et al. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol. 2009;27(30):5031-8.
30. Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters ST, Alders M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood. 2009;113(23):5951-60.
31. Hollink IH, Zwaan CM, Zimmermann M, Arentsen-Peters TC, Pieters R, Cloos J, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia. 2009;23(2):262-70.
32. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Zimmermann M, Peeters JK, Valk PJ, et al. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica. 2011;96(3):384-92.
33. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011;118 (13):3645-56.
34. Blink M, van den Heuvel-Eibrink MM, de Haas V, Klusmann JH, Hasle H, Zwaan CM. Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease. Haematologica. 2012;97(4): 632-4.
35. von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28(16):2682-9.